CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Bioimpedance devices (bioelectrical impedance spectroscopy) for detection and lymphedema

Policy governs coverage for bioimpedance (bioelectrical impedance spectroscopy, BIS) devices used for diagnosis, surveillance, or treatment of lymphedema (including subclinical secondary lymphedema) for commercial products and Medicare Advantage plans offered by Blue Cross Blue Shield - Rhode Island.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyBioimpedance devices (bioelectrical impedance spectroscopy) for detection and lymphedema

Policy CodePolicy N/A

Change TypeClarified rationale — insufficient evidence

Effective Date

Next Review Date

Key ActionClaims reporting CPT code 93702 for Medicare Advantage and commercial products may be denied or considered not medically necessary per this policy.

SourceLink

POLICY UPDATE CHANGES

Policy states bioimpedance devices are not covered/not medically necessary for diagnosis, surveillance, or treatment of lymphedema, including subclinical secondary lymphedema.

1CPT code listed as not covered

Insufficient evidenceCoverage basis

Coverage Summary

Bioimpedance spectroscopy (BIS) measures tissue impedance, which is inversely related to fluid volume, and has been proposed as a tool to detect and monitor lymphedema. Lymphedema is an accumulation of lymphatic fluid due to disrupted lymphatic drainage, most commonly secondary to cancer treatment (for example, breast cancer surgery and radiotherapy), and is characterized by nonpitting swelling with impacts on wound healing, infection risk, and quality of life.

This policy governs coverage of bioimpedance (bioelectrical impedance spectroscopy, BIS) devices for the diagnosis, surveillance, or treatment of lymphedema (including subclinical secondary lymphedema) for Medicare Advantage and commercial products. Devices using bioimpedance for these purposes are considered not covered / not medically necessary under this policy.

Policy metadata

ScopePolicy governs coverage for bioimpedance (bioelectrical impedance spectroscopy, BIS) devices used for diagnosis, surveillance, or treatment of lymphedema (including subclinical secondary lymphedema) for commercial products and Medicare Advantage plans offered by Blue Cross Blue Shield - Rhode Island.

Coverage stanceDevices using bioimpedance (bioelectrical impedance spectroscopy) are considered NOT medically necessary / not covered for use in the diagnosis, surveillance, or treatment of individuals with lymphedema, including subclinical secondary lymphedema.

StatusCURRENT

Policy titleBioimpedance devices (bioelectrical impedance spectroscopy) for detection and lymphedema

PayerBlue Cross Blue Shield - Rhode Island

Medical-Necessity Criteria

Medical Necessity Determination

Devices using bioimpedance (bioelectrical impedance spectroscopy) are considered NOT medically necessary for use in the diagnosis, surveillance, or treatment of individuals with lymphedema, including subclinical secondary lymphedema, because evidence is insufficient to determine effects on health outcomes.

ALL of the following

Use of bioimpedance devices (bioelectrical impedance spectroscopy) for diagnosis, surveillance, or treatment of lymphedema (including subclinical secondary lymphedema) is not medically necessary.
Evidence is insufficient to determine that the technology results in improvement in net health outcome (cited limitations: poor correlation with reference standards, limitations in RCT and observational studies).

Not Medically Necessary / Not Covered

The rationale is that evidence is insufficient to determine whether BIS affects health outcomes: diagnostic accuracy studies have shown poor correlation with reference standards, and available randomized and observational studies have methodological limitations that prevent demonstration of a net health benefit.

Policy change summary: The policy specifies that bioimpedance devices are not covered / not medically necessary for diagnosis, surveillance, or treatment of lymphedema, including subclinical secondary lymphedema.

Rationale for the coverage position: Evidence is insufficient and limited by poor correlation of BIS with reference standards (volume displacement or circumferential measurement), limitations of the PREVENT randomized trial (open-label design and incomplete reporting of important health outcomes), and weaknesses in observational studies (nonrandomized designs, lack of blinding, incomplete data, and inconsistent diagnostic methods).

Provider Actions

Denial Risk

Claims for BIS devices and associated CPT 93702

Claims reporting CPT code 93702 for Medicare Advantage and commercial products may be denied or considered not medically necessary per this policy.

93702

Documentation Required

Refer to member benefit documents

Benefit coverage may vary by group/contract; providers must refer to the member's Benefit Booklet/Evidence of Coverage/Subscriber Agreement to determine applicable coverage.

Background and Evidence Summary

Bioimpedance spectroscopy estimates extracellular fluid by measuring opposition to electrical current; because tissue impedance falls when interstitial fluid rises, BIS has been proposed as a diagnostic and surveillance method for lymphedema and for early detection of subclinical disease.

Lymphedema is most often secondary to lymphatic damage (for example, after breast cancer surgery or radiotherapy) and is treated with conservative measures such as elevation, compression, exercise, manual lymphatic drainage, and complete decongestive therapy; surgical reductive procedures are used for more advanced disease.

Evidence assessing BIS includes systematic reviews, one randomized controlled trial (the PREVENT trial), a prospective comparative observational study, and multiple uncontrolled observational and retrospective studies. Diagnostic accuracy studies have found poor correlation between BIS and reference standards (volume displacement or circumferential measurement). The PREVENT RCT reported fewer intervention triggers and lower progression rates with BIS versus tape measurement but was limited by open-label design and lack of reporting of key health outcomes. Comparative and observational studies have additional methodological limitations (nonrandomized design, lack of blinding, incomplete data, and inconsistent diagnostic methods), and the overall evidence is insufficient to demonstrate improved net health outcomes.

Study / Evidence	Result / Comment
PREVENT randomized controlled trial (RCT)	At median follow-up 32.9 months, BIS patients triggered intervention less often than tape-measured patients (20.1% vs 27.5%) and fewer progressed (7.9% vs 19.2%); trial limited by open-label design and lack of reporting of important health outcomes.
Diagnostic accuracy studies (systematic reviews and observational studies)	Studies found poor correlation between bioimpedance analysis and reference standards (volume displacement or circumferential measurement); overall evidence limited by methodological issues, preventing demonstration of net health benefit.
Prospective comparative observational study and retrospective studies	One prospective comparative study reported lower rates of clinical lymphedema with BIS but was nonrandomized, unblinded, had incomplete data, and lacked systematic diagnosis in controls; retrospective studies show feasibility but limited efficacy data.

Definitions

Bioimpedance spectroscopy (BIS)A method measuring resistance to electrical current to assess extracellular fluid and infer tissue fluid volume used for lymphedema assessment.

LymphedemaAccumulation of fluid due to disruption of lymphatic drainage causing nonpitting swelling, commonly after breast cancer treatment.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyBioimpedance devices (bioelectrical impedance spectroscopy) for detection and lymphedema

Policy CodePolicy N/A

Change TypeClarified rationale — insufficient evidence

Effective Date

Next Review Date

Key ActionClaims reporting CPT code 93702 for Medicare Advantage and commercial products may be denied or considered not medically necessary per this policy.

SourceLink

On This Page

OpenPayer

Bioimpedance devices (bioelectrical impedance spectroscopy) for detection and lymphedema

Coverage Summary

Medical-Necessity Criteria

Not Medically Necessary / Not Covered

Coding

Provider Actions

Background and Evidence Summary

Revision History